Critical appraisal:Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al 2011 2

From Cancer Guidelines Wiki

Critical Appraisal

Article being appraised

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011 Jul;100(1):76-85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21757247.


Applicable clinical question

Key Facts

Study Design

randomised controlled trial

Number of Patients:

23


Includes an economic evaluation

no

Evidence ratings

Level of evidence

II

Risk of bias
Low risk of bias Comments: Phase 3 study, but only minority of patients had stage II disease.


Size of effect
3 Reason for decision: No effect of intervention observed
Relevance of evidence
1 Additional comments: Outcome is survival
Result of appraisal

Jutta's tick icon.png Included




Completed by

Professor David Ball MB BS, MD, FRANCZR


Jutta's tick icon.png This appraisal has been completed.


Article
Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011 Jul;100(1):76-85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21757247.
Assigned to
User:David.ball
Topic area
Guidelines:Lung cancer/Treatment/Non-small-cell stage II inoperable
Clinical question
Form
Form:Critical appraisal


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment